NCT04897893View on ClinicalTrials.gov

Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+.

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

April 5, 2023

Study Completion Date

September 14, 2023

Conditions
Inflammation
Interventions
OTHER

Eicosapentaenoic acid monoglycerid (MAG-EPA)

MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).

Trial Locations (2)

G0C 1Y0

SCF Pharma, Maria

G0K 1P0

SCF Pharma, Rimouski

All Listed Sponsors
collaborator

Integrated Health and Social Services Centres (CISSS) de la Gaspésie

UNKNOWN

collaborator

Integrated Health and Social Services Centres (CISSS) du Bas-St-Laurent

UNKNOWN

lead

SCF Pharma

INDUSTRY